Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa randomized double-blind placebo-controlled study of single-dose intravenous it-hMSC in ischemic stroke
CTR20201323Phase 2Active
- Sponsor
- Stemedica Cell Technologies
- Start
- Jun 2021
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ischemia-tolerant mesenchymal stem cells in ischemic stroke, sponsored by Stemedica Cell Technologies. Started Jun 2021; status: active.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20201323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201323.